Press releases

2017 2016 2015 2014 2013 2012 2011 2010 2009

2017

argenx announces results of Annual General Meeting 2017

April 26, 2017

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST. 

argenx files registration statement for a proposed public offering in the United States

April 24, 2017

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering in the United States of its American Depositary Shares (ADSs) representing ordinary shares. All ADSs to be sold in the offering will be offered by argenx. The offering is subject to market and other conditions, including the effectiveness of the above-referenced registration statement. argenx’s ordinary shares are currently listed on Euronext Brussels and argenx has made an application to have its ADSs listed on the NASDAQ Stock Market under the symbol “ARGX”. 

argenx receives first preclinical milestone payment in AbbVie collaboration

April 13, 2017

Breda, the Netherlands/Ghent, Belgium argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the first of two preclinical milestones on its way to the investigational new drug (IND) filing of ARGX-115, triggering a $ 10 million payment from AbbVie. 

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

April 12, 2017

  • Interim data expected by end of 2017 

Breda, the Netherlands/Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the initiation of a Phase II trial of ARGX-110 as a monotherapy in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL). ARGX-110 is the Company’s SIMPLE Antibody™ targeting CD70. 

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

March 31, 2017

  • Topline data from the study expected in second half of 2018 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP).

argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

March 21, 2017

  • Differentiated antibody to address complement target
  • Represents latest collaboration to stem from the argenx Innovative Access Program
  • argenx granted option to license program after preclinical proof-of-concept

Breda, the Netherlands/Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. 

argenx announces Annual General Meeting of Shareholders 26 April 2017

March 15, 2017

Breda, the Netherlands – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announces that an annual general meeting of shareholders will be held on Wednesday 26 April 2017.

argenx reports fourth quarter business update and full year 2016 financial results

March 15, 2017

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its fourth quarter business update and full year results for 2016, in accordance with IFRS as adopted by the European Union. 

argenx to host conference call & webcast to report fourth quarter business update and full year 2016 financial results on March 15, 2017

March 09, 2017

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Wednesday, March 15, 2017 at 3:00 pm CET (10:00 am EDT) to discuss the 2016 financial results, as well as provide a fourth quarter business update.  

argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia

March 06, 2017

 

  • Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia
  • Represents latest collaboration to stem from the argenx’s Innovative Access Program
  • argenx is eligible to receive a double-digit royalty on ARGX-116 related income

Breda, the Netherlands/Ghent, Belgium argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslipidemia. This collaboration is the latest to stem from the argenx Innovative Access Program.  

argenx announces intention to conduct a registered public offering in the United States

March 01, 2017

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States. The timing, number of ordinary shares and price of the proposed offering have not yet been determined.

argenx to Present at Cowen & Co 37th Annual Healthcare conference

February 28, 2017

Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer Tim Van Hauwermeiren, will present a company overview at the Cowen & Co. 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.

argenx announces extension of therapeutic antibody alliance with Shire

February 27, 2017

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.

argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference

February 09, 2017

Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its Chief Executive Officer Tim Van Hauwermeiren will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 1:30 p.m. ET in New York City. 

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

January 09, 2017

  • Topline data from the study expected in second half of 2018 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG). 

2016

argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine

December 29, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the publication of new preclinical data on the CD70/CD27 pathway that provide further rationale for ARGX-110 therapy for the treatment of acute myeloid leukemia (AML). ARGX-110, a SIMPLE Antibody™ targeting CD70, is currently being evaluated in a Phase I/II study in combination with azacitidine in newly diagnosed AML patients.

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

December 15, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the initiation of a Phase I/II clinical trial of ARGX-110 in combination with azacitidine in newly diagnosed, elderly acute myeloid leukemia (AML) patients. ARGX-110 is the Company’s SIMPLE Antibody™ targeting CD70. Azacitidine is a hypomethylating agent that upregulates CD70 expression on AML blasts, and is currently the standard of care treatment for elderly AML patients. 

argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting

December 02, 2016

Workshop to occur on Sunday December 4th at 11:00 am PT 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will provide updates on its two lead programs, ARGX-113 and ARGX-110, during a workshop being held today in conjunction with the American Society of Hematology (ASH) Annual Meeting. 

argenx to Present at Upcoming Investor Conferences

November 08, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that management will present at several upcoming investor conferences in November:

argenx Reports Third Quarter 2016 Financial Results and Provides Business Update

October 27, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced financial results for the third quarter ended 30 September 2016.

Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™

October 05, 2016

argenx’s specific drug candidates include ARGX-113 for myasthenia gravis, ARGX-110 for cancer immunotherapy, and ARGX-111 for c-MET

London UK / Breda, the Netherlands / Ghent, Belgium Based on its recent analysis of the therapeutic antibody engineering market, Frost & Sullivan recognises argenx N.V. with the 2016 European Frost & Sullivan Award for Technology Innovation. argenx’s SIMPLE Antibody™ discovery platform is a huge improvement on conventional antibody discovery platforms because it yields an unprecedented epitope coverage, allowing to interact with the disease biology in a much more precise manner. The application diversity of the platform enables it to generate a wide array of antibodies for different types of cancer and autoimmune disorders.

argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York

September 22, 2016

  • Myasthenia gravis and immune thrombocytopenia named as initial indications for Phase 2 studies of ARGX-113
  • T-cell lymphoma and acute myeloid leukemia named as indications for Phase 2 combination studies for ARGX-110  

 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided highlights from its lead pipeline programs, ARGX-113 and ARGX-110, during its R&D in New York City.

argenx to host inaugural R&D day and webcast on September 22, 2016

September 15, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.  

argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results

August 26, 2016

  • Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113
     in healthy volunteers
  • Phase 2 study in first auto-immune indication planned to start by year-end
  • Cash position strengthened by $40M upfront payment from AbbVie and
    €30M private placement

Management to host conference call today at 3 pm CET / 9 am EDT

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its second quarter business update and half year financial results for 2016, in accordance with IFRS as adopted by the European Union. 

argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016

August 19, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, August 26, 2016 at 3:00pm CET (9:00am EDT) to discuss financial results for the first half of 2016, as well as to provide a second quarter business update.

argenx to Present at Wedbush PacGrow Healthcare Conference

August 10, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 17, 2016 at 8:35 am ET.

The presentation will be webcast live and may be accessed on the argenx website at www.argenx.com or by clicking here. A replay of the webcast will be available for 90 days following the presentation. 

argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers

June 30, 2016

  • Data show potent reduction of IgG levels of up to 85% and a favorable safety and tolerability profile
  • Phase 2 trial in myasthenia gravis expected to begin by end of 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced initial results from its Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers.  The compound continues to show favorable safety and tolerability across multiple doses and dosing regimens with promising pharmacodynamics effects relating to speed, depth and duration of IgG reduction. 

argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016

June 10, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the presentation of efficacy and safety data from its Phase 1 expansion study of ARGX-110 in patients with T-cell lymphoma (TCL) during an e-poster session at the European Hematology Association (EHA) Annual Congress (Copenhagen, Denmark). 

argenx successfully closes €30 million private placement

June 03, 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

June 03, 2016

  • Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA) presenting efficacy and safety data from its ARGX-111 Phase 1 expansion study in patients with MET amplified tumors. The data confirm ARGX-111 to have a favorable safety profile and to continue to show signs of anti-tumor activity. The abstract can be accessed here

 

argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors

June 01, 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

argenx reports first quarter 2016 financial results and provides business update

May 11, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced financial results for the first quarter ended 31 March 2016. 

argenx announces results of Annual General Meeting 2016

April 28, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET. 

argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

April 21, 2016

  • argenx Management to Discuss Collaboration on Conference Call Today at 6 pm CET / noon EDT

BREDA, THE NETHERLANDS/GHENT, BELGIUM and NORTH CHICAGO, Ill., AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells. 

argenx announces Annual General Meeting of Shareholders 28 April 2016

March 16, 2016

Breda, the Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Thursday 28 April 2016.

argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis

March 16, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reported that its partner Bird Rock Bio (formerly RuiYi), a company focused on the discovery and development of novel biologic therapies, has announced  that gerilimzumab, a novel SIMPLE AntibodyTM neutralizing the IL-6 cytokine,  has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing. 

argenx reports fourth quarter business update and full year 2015 financial results

March 11, 2016

  • Clinical programs in severe auto-immune diseases and oncology
  • Supported by strong financial position
  • Management to host conference call today at 3 pm CET / 9 am EDT

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and full year results for 2015, in accordance with IFRS as adopted by the European Union.

The full year results will be discussed during a conference call and webcast presentation today at 3 pm CET / 9 am EDT. To participate in the conference call, please select your phone number below, and use the confirmation code 61559035. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016

March 03, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, 11 March 2016 at 3:00 pm CET (9:00 am ET) to discuss the 2015 financial results, as well as provide a fourth quarter business update.  

argenx: Home Member State Selection

February 26, 2016

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that following the implementation of the amended EU Transparency Directive (2013/50/EU), arGEN-X NV is required to publicly announce its Home Member State. In accordance with this regulation, the company announces that its Home Member State is the Netherlands.

argenx opens clinical trial sites in South Korea for ARGX-111 program

February 18, 2016

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced the opening of three clinical trial sites in South Korea for the recruitment of MET-amplified cancer patients for the Phase 1 safety expansion cohort of ARGX-111. 

argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference

February 05, 2016

Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City (NY, USA) on Thursday, February 11, 2016 at 1:50pm ET.

argenx receives milestone payment in LEO Pharma collaboration

February 02, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has received a milestone payment in connection with its collaboration with LEO Pharma. The companies have selected a lead cell line for manufacture of the licensed SIMPLE AntibodyTM candidate, in development for the treatment of inflammatory skin conditions.

argenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors

January 22, 2016

argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors

January 19, 2016

argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

January 06, 2016

  • Favourable safety and tolerability profile observed
  • Rapid reduction of IgG levels

Breda, the Netherlands / Ghent, Belgiumargenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has completed the dose-escalation part of a Phase 1 study of ARGX-113. Initial results show the compound to be safe and well-tolerated across all doses in healthy volunteers.

2015

argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program

December 07, 2015

Workshop and webcast to occur at 12:00 pm ET today

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host a workshop and webcast to discuss new ARGX-110 data, in conjunction with the American Society of Hematology (ASH) Annual Meeting. The data on ARGX-110, a novel anti-CD70 therapeutic antibody, include topline clinical results in T-cell lymphoma (TCL) and preclinical data in acute myelogenous leukemia (AML). 

argenx reports third quarter 2015 financial results and provides business update

November 17, 2015

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the third quarter ended 30 September 2015. 

argenx to Present at Key Investor Conferences

October 29, 2015

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren and Chief Financial Officer, Eric Castaldi, will be participating in several upcoming investor conferences in November and December.

arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders

October 22, 2015

  • Potential breakthrough therapy for treatment of autoimmune crisis
  • Fourth arGEN-X drug candidate entering human trials in 6 years of operations

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the completion of the first human dosing of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis.

arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6

September 23, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies, has announced the first human dosing of Gerilimzumab, a novel monoclonal antibody neutralizing the IL-6 cytokine, for the treatment of autoimmune disorders including rheumatoid arthritis.

arGEN-X Announces Half-Year Results For 2015

August 25, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced its financial results for the first half of 2015 (six-month period ended June 30, 2015).

arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015

August 19, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces it will report its business update and financial results for the first half of 2015 on Wednesday, August 26, 2015.

arGEN-X to Present at Wedbush PacGrow Healthcare Conference

August 06, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 12, 2015 at 1:20pm ET.

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

July 30, 2015

  • Collaboration demonstrates potential of ARGX-110 in overcoming treatment resistance in chronic myelogenous leukemia (CML)
  • Preclinical results published in Science Translational Medicine

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors.

Change to the Board of Directors

July 15, 2015

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that non-executive director Michael B. Sheffery, representing Orbimed Advisors, will resign from the Board of Directors per 26 August 2015.

Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML

June 18, 2015

Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today presented preliminary results from an ongoing Phase I study of ARGX-110 in patients with T-cell lymphoma at the 13th International Conference on Malignant Lymphoma (Lugano, Switzerland; 17-20 June, 2015) in the ‘Novel Agents’ session.

arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT

June 01, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Jefferies 2015 Global Healthcare Conference in New York City (NY, USA) on Tuesday, 2 June 2015 at 8:00am EDT.

arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO

May 29, 2015

  • Safe dose established for next stage studies
  • Biological activity observed in MET-amplified cancer patient

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, will present the results of a Phase I, first-in-human dose escalation study of ARGX-111, a monoclonal antibody targeting c-Met in patients with solid tumors, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The company will present an abstract of the data on Saturday, May 30th, from 08:00am – 11:30am as part of the poster session on Development Therapeutics.

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

May 21, 2015

Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance in which they will collaborate to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions.

arGEN-X Awarded €1.5 Million IWT Grant to Advance the Application of NHance® Fc Modifications in Therapeutic Antibodies

May 19, 2015

Breda, The Netherlands / Ghent, Belgium, – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.

arGEN-X – First Quarter 2015 Financial Results and Business Update

May 15, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the first quarter ended 31 March 2015.

arGEN-X Announces Results of Annual General Meeting 2015

May 13, 2015

Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.

arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy

April 23, 2015

  • Results on ARGX-115 published in Science Translational Medicine indicating inhibition of immune checkpoint GARP in in vivo mouse model

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, and de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE) today announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint. These findings were published in the leading journal Science Translational Medicine and suggest potential for the antibody candidate in cancer immunotherapy.

arGEN-x N.V. Announces Changes to the Board of Directors

April 14, 2015

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the resignation of Non-executive Directors Dr. Bruno Montanari and Dr. Harrold van Barlingen from the Board of Directors per 13 May 2015.

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers

April 09, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has advanced ARGX-111, a best-in-class highly differentiated SIMPLE Antibody™ targeting c-MET driven malignancies, into the safety and efficacy expansion part of its Phase 1b study. The objective of the expansion cohort is to further characterize the safety of ARGX-111 in cancer patients with MET amplified tumors, and to evaluate efficacy signals in order to select the indications to be studied in Phase 2 clinical development.

arGEN-X Announces Annual General Meeting of Shareholders 13 May 2015

April 01, 2015

Breda, the Netherlands - arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Wednesday 13 May 2015.

arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results

March 18, 2015

Breda, the Netherlands / Ghent, Belgium arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and the consolidated full year results for 2014, which have been prepared in accordance with IFRS as adopted by the European Union.

arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

March 13, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.

arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015

March 11, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will report its fourth quarter business update and its full year 2014 financial results after market close on Wednesday, 18 March 2015.

arGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy

March 04, 2015

  • ARGX-115 re-activates immunity to cancer
  • First-in-class therapeutic antibody targeting GARP, a novel immune checkpoint
  • First candidate to be licensed under Company’s Innovative Access Program

Breda, the Netherlands/Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has exercised its option to exclusively license a first-in-class, preclinical therapeutic antibody candidate, now ARGX-115, to target GARP, a novel immune checkpoint with potential in cancer immunotherapy. ARGX-115 was discovered under arGEN-X’ Innovative Access Program with de Duve Institute / Université Catholique de Louvain (UCL) / WELBIO (BE).

arGEN-X Presents ARGX-111 at Targeted Anticancer Therapies

March 02, 2015

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, presented clinical potential of ARGX-111 in hematological malignancies and suppression of metastasis at Targeted Anticancer Therapies (TAT), Paris, France.

Lonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies

February 18, 2015

Basel, Switzerland, Ghent, Belgium and Breda, The Netherlands – Lonza, a global leader in biological manufacturing and arGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. The license secures long-term access for arGEN-X and its strategic partners to Lonza’s proprietary GS Xceed™ System for creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals.

arGEN-X Launches Innovative Access Program

January 12, 2015

  • Program extends reach of proprietary SIMPLE Antibody™ platform and creates potential for future value creation
  • First collaborations with U.S.-based biotech company active in dyslipidemia and the de Duve Institute in cancer immunotherapy

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has initiated its Innovative Access Program, providing its SIMPLE Antibody™ platform to academic centers of excellence and emerging biotech companies through collaboration. The goal of this program is to exploit the proven power of the SIMPLE Antibody™ platform in therapeutic areas complementary to arGEN-X’s strategic focus.

2014

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire

December 11, 2014

  • Shire to take one or more collaborative product candidates into preclinical development

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates created out of a 2012 therapeutic antibody alliance between the two companies. As a result of the exercise, arGEN-X will receive a milestone payment from Shire.

arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model

December 08, 2014

  • Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the presentation of preclinical data at the American Society of Hematology (ASH) Annual Meeting highlighting the potential of the CD70 pathway as a targetable mechanism to overcome drug resistance in chronic myelogenous leukemia (CML). The data show that co-treatment of ARGX-110, the Company’s anti-CD70 therapeutic antibody, and imatinib, a first-line BCR/ABL-specific tyrosine kinase inhibitor (TKI), eradicates the disease-initiating CML stem cells, a cell population often resistant to TKI therapy.

arGEN-X – Third Quarter Business Update

November 14, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update for the third quarter 2014 and financial highlights for the nine months ended 30 September 2014.

arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas

November 11, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has initiated a clinical efficacy evaluation of ARGX-110, its investigational anti-CD70 therapeutic antibody, in patients with relapsed/refractory CD70-positive T-cell lymphomas. The evaluation will be conducted as an expansion arm of the ongoing Phase 1b study of ARGX-110.

arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia

November 03, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 in patients with relapsed or refractory Waldenström’s macroglobulinemia. ARGX-110 is a novel anti-CD70 antibody currently being evaluated in a Phase 1b study in hematological and solid cancers in Europe.

arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110

October 15, 2014

  • Based on evidence of activity, T-cell lymphomas selected as indication for initial efficacy studies

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of the first expansion cohort of 15 patients with CD70-positive hematological malignancies, part of an ongoing open-label Phase 1b trial with ARGX-110, a novel anti-CD70 therapeutic antibody.

arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b Expansion Trial with ARGX-110

September 18, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of a first cohort of 15 patients with CD70-positive solid tumors into an open-label Phase 1b expansion trial with ARGX-110, a novel anti-CD70 therapeutic antibody. Recruitment of a second cohort of 15 patients with CD70-positive hematological malignancies is ongoing. The primary objective of the expansion trial is to select one or more indications to take forward into further clinical trials.

arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States

September 17, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, is pleased to announce the grant of key patents in the United States relating to its two lead clinical candidates ARGX-110 and ARGX-111.

arGEN-X Appoints Petercam NV as Liquidity Provider to Facilitate Trading on Euronext Brussels

September 15, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today that it has appointed Petercam NV as a liquidity provider for the Company’s common shares currently listed on Euronext Brussels under the trading symbol ARGX.

arGEN-X – Business Update and First Half 2014 Results

August 27, 2014

Breda, the Netherlands / Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update and announces its financial results for the first half of 2014 (six-month period ended 30 June 2014).

arGEN-X Announces Positive Preclinical Results for ARGX-113

August 19, 2014

  • Data support ARGX-113 as a potential breakthrough concept for management of flares in severe autoimmune diseases

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the results of a preclinical study assessing the pharmacokinetic and pharmacodynamic (PK/PD) behaviors of ARGX-113, the Company’s most advanced autoimmune product candidate. The data proved ARGX-113 to be highly effective in rapidly clearing a tracer antibody from circulation in a dose-dependent manner in non-human primates, thus acting as a surrogate of autoantibody clearance.

arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period

August 11, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (“arGEN-X”, Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces today the partial exercise of the over-allotment option by KBC Securities (the “Stabilization Manager”) acting on behalf of KBC Securities and Kempen & Co (the “Joint Global Coordinators”) and Petercam (the “Co-Lead-Manager”); and the end of the stabilization period, in relation to its Initial Public Offering that ended on 8 July 2014 (the “IPO”).

arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference

August 05, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush 2014 Life Sciences Management Access Conference in New York City (NY, USA) on Tuesday, 12 August 2014 at 3:05pm EDT.

arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels

July 08, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (“arGEN-X”), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering, which was launched on 23 June 2014 (the “IPO” or the “Offering”). arGEN-X shares will be listed on Euronext Brussels and begin trading on an “if-and-when-issued-or-delivered” basis on Thursday 10 July 2014 under the symbol “ARGX”.

arGEN-X Launches Initial Public Offering on Euronext Brussels

June 20, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the launch of its Initial Public Offering on Euronext Brussels.

arGEN-X Announces Intention to Launch an Initial Public Offering on Euronext Brussels

June 10, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its intention to raise new funds through an Initial Public Offering on Euronext Brussels.

arGEN-X Enters Long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies

June 04, 2014

  • Significantly expanded relationship created on back of collaboration success

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. Under the agreement, arGEN-X will bring its entire suite of human antibody discovery technologies to a partnership focused on multiple targets aligned with Shire’s therapeutic focus. The multi-year initiative aimed at helping augment the Shire development pipeline follows an initial research and development collaboration undertaken in March 2012.

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

May 29, 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA).

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

May 28, 2014

Breda, the Netherlands – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms.

arGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program

April 07, 2014

  • New findings to be presented at the American Association for Cancer Research annual meeting

Breda, The Netherlands/Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody™ platform has identified four ‘hotspots’ on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET signalling is involved in cancer proliferation and metastasis and is activated by hepatocyte growth factor (HGF) in multiple cancers.

arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board

April 04, 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, announces that it has appointed Dr. Werner Lanthaler to its Supervisory Board.

arGEN-X receives two preclinical milestone payments under collaboration with Shire

January 13, 2014

  • Enters into pilot research agreement with Boehringer Ingelheim

Breda, the Netherlands / Ghent, Belgium– arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.

arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

January 07, 2014

  • Study supported by a €3.5 million IWT grant from the Flemish Government

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive cancer patients with either haematological or solid tumors, and to evaluate efficacy in order to select the indications to be studied in Phase II clinical development. Top-line results are expected in about 12 months. The study is being supported by a €3.5 million grant from the Flemish Government’s Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).

2013

ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study

December 17, 2013

Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected to report top-line results approximately 12 months later.

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

November 04, 2013

  • Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, has raised EUR 5 million ($6.8 million) as an extension of its series B financing round from the Flemish investment company PMV as a new investor. arGEN-X’ series B round, which had its first close in December 2011, now totals EUR 32.5 million ($44 million). 

arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer

November 04, 2013

Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties will closely collaborate to use arGEN-X' SIMPLE Antibody™ technology in validating the biology of a novel cancer immunomodulation target and creating functional leads with therapeutic potential. arGEN-X has an option to develop and commercialize resulting antibody drug candidates on an exclusive basis, from which both parties will share the rewards.

arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire

September 19, 2013

Breda, the Netherlands and Ghent, Belgium September – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody™ research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration. 

arGEN-X initiates Phase Ib study of ARGX-111 in cancer

September 17, 2013

  • SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors

Breda, the Netherlands, and Ghent, Belgium – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. 

arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7

September 12, 2013

  • Breakthrough data to be presented during the ‘Discovery on Target’ conference in Boston, MA, USA on September 25, 2013

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

arGEN-X grants license to its NHance™ antibody half-life extension technology

August 06, 2013

  • Meeting the Increasing Demand for Technologies that Enable Antibody Product Differentiation

Breda, the Netherlands – arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. Both licenses granted to date are with companies dedicated to developing and commercializing antibody-based therapeutics with clear clinical benefits.

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013

April 26, 2013

  • Presentations will highlight significant progress made towards development of novel therapeutic antibodies

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that Professor Hans de Haard (Chief Scientific Officer) and Dr. Debbie Allen (Senior Director, Business Development) will each present at the Ninth Annual PEGS (Protein Engineering Summit). The event takes place April 29-May 3, 2013 at the Seaport World Trade Center (Boston, MA, USA). 

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

April 24, 2013

  • First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development.

arGEN-X announces preclinical development of ARGX-112 for dermatology

March 25, 2013

  • ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

arGEN-X expands its therapeutic antibody alliance with Shire

January 07, 2013

  • New discovery program initiated within 12 months of collaboration start

Breda, the Netherlands – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody™ discovery platform to create novel human antibody therapeutics addressing diverse rare and unmet diseases being pursued by Shire. 

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

January 07, 2013

Breda, the Netherlands, and Ghent, Belgium – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery. 

2012

arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform

December 06, 2012

Breda, the Netherlands, and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of highly differentiated human monoclonal antibody therapeutics has received its first Notice of Allowance from the United States Patent and Trademark Office (USPTO) in connection with a portfolio of patent filings related to its SIMPLE Antibody™ discovery platform.

arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012

November 06, 2012

  • ARGX-110 is highly potent and selective for CD70, a key target in cancer and autoimmune diseases

Breda, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, will disclose the exciting attributes of its most advanced SIMPLE Antibody™ candidate, ARGX-110, at the PEGS Summit, Nov 6-8, 2012 in Vienna, Austria. The exciting potential of ARGX-110 will be presented by Dr Karen Silence, Research Fellow and ARGX-110 project leader.

arGEN-X appoints Dr. David L. Lacey to its supervisory board

October 25, 2012

Breda, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody

October 04, 2012

  • Initial Development Strategy for Highly Potent Antibody Will be Focused on China

LA JOLLA, CA, BREDA, THE NETHERLANDS, and GHENT, BELGIUM  – RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X.

Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner

May 14, 2012

  • Signature Award recognizes life sciences companies developing unique technologies

Needham, Massachusetts – Cambridge Healthtech Associates™ (CHA™) today announced that arGEN-X is the winner of its inaugural Signature Award™.

arGEN-X granted first US patent covering its unique NHance™ technology

April 24, 2012

Rotterdam, the Netherlands and Ghent, Belgium  – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has been granted the first patent covering its novel NHance™ technology.

arGEN-X launches NHance™ technology to generate better human antibody therapies

March 19, 2012

  • Adds a second proprietary technology to leverage the power of the SIMPLE Antibody™platform

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X announces today the launch of NHance™, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

arGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel

March 19, 2012

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has strengthened its management team with two key hires. Alain Thibault, MD joins the Company as Chief Medical Officer, while Jacobus (Koos) Rasser, PhD, JD will serve as IP Counsel.

arGEN-X enters into a therapeutic antibody alliance with Shire

February 28, 2012

  • Human antibody product collaboration in rare diseases

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

arGEN-X advances a third therapeutic antibody program into preclinical development

February 08, 2012

  • ARGX-111 is an anti-c-Met antibody with broad applicability in cancer

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.

2011

arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round

December 01, 2011

  • Funds will be used to progress differentiated therapeutic antibody programs into clinical development

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed. The fundraising was co-led by OrbiMed Advisors (USA) and Seventure Partners (France), with the existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB also participating. OrbiMed’s founding partner, Dr Mike Sheffery, will join the arGEN-X Supervisory Board.

arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets

November 30, 2011

Rotterdam, The Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets. The grant was awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), and is the third award the Company has received from the institute, totalling €4.1 million to date.

arGEN-X presents significant progress at Biopharm America 2011

September 07, 2011

  • SIMPLE Antibody™ platform continues to demonstrate clear advantages in therapeutic antibody discovery

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year’s significant corporate progress during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (www.ebdgroup.com/bpa/).

arGEN-X announces non-exclusive license with BioWa for Potelligent® technology

July 26, 2011

  • SYNERGISTIC EFFECT OF APPLYING POTELLIGENT® TO SIMPLE ANTIBODIES™ CREATES BEST-IN-CLASS ANTIBODY THERAPEUTICS

Rotterdam, the Netherlands; Ghent, Belgium; Princeton, NJ, USA – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology.

arGEN-X initiates a second pre-clinical development program in under 18 months from start of operations

May 16, 2011

  • ARGX-110 TO TARGET AUTOIMMUNE, INFLAMMATION AND ONCOLOGY INDICATIONS

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development in less than 18 months since the Company began its operations.

arGEN-X signs discovery and development alliance with Lilly

January 05, 2011

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced it has entered into an alliance with Eli Lilly and Company (“Lilly”) to discover and develop novel therapeutic antibody products against targets submitted by Lilly.

2010

arGEN-X appoints Dr Debbie Allen as Senior Director Business Development

November 05, 2010

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced the appointment of Dr Debbie Allen as Senior Director Business Development. Dr Allen brings to arGEN-X more than 12 years of corporate and business development experience with small and large biotech companies.

arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development

September 27, 2010

  • ARGX-109 and Two Further Human Antibody Development Candidates Generated From Unique SIMPLE Antibody™ platform

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), today announced that it has received a €1.5 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space.

arGEN-X granted broad patent covering its unique simple antibody™ platform

July 08, 2010

  • Novel Platform Set to Transform Human Therapeutic Antibody Discovery & Development

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

arGEN-X concludes EUR 12.5 million Series A financing round

April 20, 2010

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Crédit Agricole Private Equity and VIB (the prestigious Flemish research institute).

arGEN-X simple antibody™ platform set to transform therapeutic antibody discovery & development

March 01, 2010

  • SIMPLE Antibody™ Platform delivers unprecedented choice of ultra-potent functional antibody leads against challenging soluble and cell surface targets.
  • ARGX-109, a fully human mAb targeting autoimmune, inflammation and oncology indications, enters preclinical development in less than 12 months from start of discovery.

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, announces that it will provide an update on the development of this unique platform and its own antibody pipeline during the BIO-Europe Spring event in Barcelona (March 8-10, 2010).

2009

arGEN-X opens new R&D facility in Flanders

November 10, 2009

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced that it has opened a new R&D subsidiary in Flanders – arGEN-X BVBA. The facility is supported by a €1.3 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is intended to become a center of excellence dedicated to the discovery and development of novel therapeutic antibodies based on arGEN-X’ SIMPLE Antibody™ platform.

arGEN-X raises €9.5 million to put SIMPLE Antibody™ platform to work

September 10, 2009

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced the successful first closing of its Series A equity financing round. The Company raised  EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months.